Tilly’S, Inc.
$175.16M- Market cap
- $52.82M
- Debt
- +$168.65M
- Cash
- −$46.31M
Capital structure 24% equity / 76% debt · EV / Revenue 0.32x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $52.82M · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: TLYS stock price at discount vs ANIP $4.41 current versus $33.36 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIP's multiple
Implied fair value · at TLYS's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TLYS FY 2026 (ended Jan 31, 2026) · ANIP FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 24% equity / 76% debt · EV / Revenue 0.32x
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
ANIP carries the larger enterprise value at $1.63B against $175.16M; TLYS trades on the lower EV / Revenue multiple (0.32x vs 1.84x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TILLY’S, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.98x
0.57x
Net debt / EBITDA
Leverage against operating earnings
-17.50x
0.11x
Cash and equivalents
Liquid reserves on the balance sheet
$46.31M
$285.59M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMERICAN EAGLE OUTFITTERS INC
TLYS vs AEO
ABERCROMBIE & FITCH CO /DE/
TLYS vs ANF
GAP INC
TLYS vs GAP
Zumiez Inc
TLYS vs ZUMZ
SUPERNUS PHARMACEUTICALS, INC.
TLYS vs SUPN
PERRIGO Co plc
TLYS vs PRGO
Viatris Inc
TLYS vs VTRS
Organon & Co.
TLYS vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
TLYS vs TEVA
$168.65M
$309.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.